Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KPC PharmaceuticalsSHSE:600422 +1.52%64 Days Payable is 103.71 as of Jun. 2026, which is 35% above its 10-year median of 77.08. GuruFocus rates SHSE:600422 with a GF Score™ of 64/100 and a GF Value™ of ¥10.04 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 924 Drug Manufacturers companies, KPC Pharmaceuticals ranks worse than 52.6% on this metric.
The historical rank and industry rank for KPC Pharmaceuticals's Days Payable or its related term are showing as below:
SHSE:600422'
s Days Payable Range Over the Past 10 Years
Min: 57.8 Med: 77.08 Max: 87.22
Current: 84.52
During the past 13 years, KPC Pharmaceuticals's highest Days Payable was 87.22. The lowest was 57.80. And the median was 77.08.
SHSE:600422's Days Payable is ranked worse than 52.6% of 924
companies
in the Drug Manufacturers industry
Industry Median: 88.8
vs SHSE:600422: 84.52
KPC Pharmaceuticals's Days Payable
increased
from Jun. 2025 (85.95) to Jun. 2026 (103.71).
It may suggest that KPC Pharmaceuticalsdelayed paying its suppliers.
The historical data trend for KPC Pharmaceuticals's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, KPC Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KPC Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, KPC Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where KPC Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
KPC Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KPC Pharmaceuticals (SHSE:600422) has a Days Payable of 103.71 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on KPC Pharmaceuticals and its competitors. This is 35% above median its historical median of 77.08. Over the past decade, KPC Pharmaceuticals' Days Payable has ranged from 57.80 to 87.22. According to the industry distribution chart, KPC Pharmaceuticals ranks #486 out of 924 companies in the Drug Manufacturers industry, placing it in the top 52.6%.
Is KPC Pharmaceuticals' Days Payable too high?
KPC Pharmaceuticals' current Days Payable of 103.71 is 35% above median its 10-year median of 77.08. Over the past 10 years, this metric has ranged from a low of 57.80 to a high of 87.22. The Drug Manufacturers industry median Days Payable is 88.80. KPC Pharmaceuticals' value of 103.71 is 16.8% above this industry median. Based on the distribution chart, KPC Pharmaceuticals ranks #486 out of 924 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, KPC Pharmaceuticals has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does KPC Pharmaceuticals' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, KPC Pharmaceuticals ranks #486 out of 924 companies for Days Payable. This places KPC Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 88.80. KPC Pharmaceuticals' value of 103.71 is 16.8% above this benchmark. Historically, KPC Pharmaceuticals' own Days Payable has ranged from 57.80 to 87.22 over the past decade. While the company's 10-year median is 77.08 vs. the industry median of 88.80, KPC Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.80, based on 924 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. KPC Pharmaceuticals's current Days Payable of 103.71 is 16.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on KPC Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KPC Pharmaceuticals's current Days Payable is 103.71, which is 35% above median its own 10-year median of 77.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KPC Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, KPC Pharmaceuticals (SHSE:600422) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.04, compared to a current price of ¥8.69 — trading 13.4% below its estimated fair value. The current Days Payable is 103.71, which is 35% above median its 10-year median of 77.08 and 16.8% above the Drug Manufacturers industry median of 88.80. KPC Pharmaceuticals' overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For KPC Pharmaceuticals (SHSE:600422), the current Days Payable is 103.71 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KPC Pharmaceuticals (SHSE:600422) Overvalued in 2026?
Based on GuruFocus' analysis, KPC Pharmaceuticals stock appears to be undervalued.
The current stock price of ¥8.69 is trading 13.4% below its estimated GF Value™ of ¥10.04.
GuruFocus considers KPC Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for SHSE:600422:
Days Payable: 103.71 (35% above median its 10-year median of 77.08)
GF Value™: ¥10.04 vs. price of ¥8.69 (13.4% below fair value)
Industry Position: 16.8% above the Drug Manufacturers median (#486 of 924)
No single metric tells the full story. See the SHSE:600422 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
64GF Score
Get the complete analysis for SHSE:600422
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600422 has been successfully added to your 
